TCRX is trading at $0.83 (-5.24%) following a weak open. - The downward move follows recent positive initial data from its ALLOHAâ„¢ Phase 1 study for TSC-101 in heme malignancies, announced on June 22, 2026. - Investors may be re-evaluating the implications of the data or responding to broader market sentiment for thinly traded biotech names. - TScan Therapeutics is also scheduled to participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026.